Docstoc

4 stages of lung cancer

Document Sample
4 stages of lung cancer Powered By Docstoc
					                                   Principal Investigator/Program Director (Last, first, middle):   Kurie, Jonathan M.

                                                             BIOGRAPHICAL SKETCH
                                 Provide the following information for the key personnel in the order listed for Form Page 2.
                                       Follow the sample format for each person. DO NOT EXCEED FOUR PAGES.


    NAME                                                                         POSITION TITLE

    Jonathan M. Kurie, M.D.                                                      Associate Professor of Medicine

    EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

                      INSTITUTION AND LOCATION                                    DEGREE                YEAR(s)                 FIELD OF STUDY
                                                                               (if applicable)
    University of North Carolina, Chapel Hill, NC                            B.A.                               1979      Chemistry
    East Carolina University, Greenville, NC                                 M.D.                               1983      Medicine

A. Positions and Honors

Positions and Employment
07/01/83 - 06/30/84   Intern, Medical College of Georgia, Department of Medicine, Augusta, Georgia,
                      30912
07/01/84 - 06/30/86   Resident, Medical College of Georgia, Department of Medicine, Augusta, Georgia, 30912
09/01/86 - 06/30/88   Biotechnology Fellow, National Institutes of Health, Laboratory of Genetics, Bethesda,
                      Maryland, 20892, Mentor: Dr. Michael Potter
07/01/88 - 06/30/92   Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center, New York, New York
                      10021, Mentor: Dr. Ethan Dmitrovsky.
07/01/92 - 06/30/93   Instructor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New
                      York 10021
07/01/93 – 08/31/99   Assistant Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology,
                      The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
09/01/99 – Present    Associate Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology,
                      The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030

Other Experience and Professional Memberships
9/86                   Diplomate, American Board of Internal Medicine
9/91                   Diplomate, Medical Oncology Subspecialty, ABIM

Honors
1978-1979                         University of North Carolina, Academic Dean's List
1983                              East Carolina University, Department of Pathology
                                  Scholarship Award National
1990-1993                         Institutes of Health, National Research Service Award,
1990-1994                         #1F32CA08940-01
1992                              Schering Corporation ASCO Travel Award
1993                              M. D. Anderson Cancer Center, University Cancer Foundation Award
1994-1995                         American Cancer Society Career Development Award ( terminated
1994-1996                         early becauseof R29 award)
1995-1996                         M. D. Anderson Cancer Center, Physicians Referral Service Award
1999-2001                         Sidney Kimmel Scholar Award
2001                              American Society for Clinical Investigation

B. Selected peer-reviewed publications
1. Han G-H, Dohi DF, Lee H-Y, Rajah R, Walsh FL, Hong WK, Cohen P, Kurie JM. All-trans retinoic acid increases
    transforming growth factor-2 and insulin-like growth factor binding protein-3 expression through a retinoic acid
    receptor--dependent signaling pathway. J Biol Chem 272:13711-13716, 1997.
2.  Xu X-C, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie, JM, Hong WK, Lotan R. Selective suppression of
    nuclear retinoic acid receptor  in non-small cell lung cancer in vivo: Implications in lung cancer development. J Natl
    Cancer Instit 89:(9), 624-629, 1997.
3. Mao L, Lee JS, Kurie JM, Fan YH, Lippman S, Lee JJ, Ro JY, Broxson A, Yu R, Morice R, Kemp B, Khuri F, Walsh

   PHS 398/2590 (Rev. 05/01)                                                  Page _______                           Biographical Sketch Format Page   
                                   Principal Investigator/Program Director (Last, first, middle): Kurie, Jonathan M.
          G, Hittelman W, Hong WK. Clonal genetic alternations in the lungs of current and former smokers. J Natl Cancer
          Instit 89:857-862, 1997.
4.        Lee H-L, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM. All-trans retinoic
          acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells
          through a retinoic acid receptor-dependent signaling pathway. J Clin Invest 101:1012-1019, 1998.
5.        Lee H-Y, Walsh GL, Dawson MI, Hong WK, Kurie JM. All-trans retinoic acid inhibits jun N-terminal kinase-
          dependent signaling pathways. J Biol Chem 273:7066-7071, 1998.
6.       Lee H-Y, Chaudhary J, Hong WK, Kurie JM. Suppression of c-fos gene transcription with malignant transformation
          of human bronchial epithelial cells. Oncogene 16:3039-3046, 1998.
7.       Kurie JM, Lee JS, Morice RC, Walsh GL, Khuri FR, Broxson A, Ro JY, Yu R, Hong WK. Autofluorescence
          bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer
          Instit 90:991-995, 1998.
8.       Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-Hydroxyphenyl) retinamide than
          all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4:1345-1355,
          1998.
    9.   Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Nagggar AK, Fossella FV, Glisson BS,
          Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene Therapy
          for Non-Small Cell Lung Cancer: A Preliminary Report of a Phase I Trial of Adenoviral p53 Gene Replacement.
          Semin Onco 25:33-37, 1998
10.      Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, Hong WK, Lotan R. Differential responses of
          normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer
          Res 5:431-437, 1999.
11.       Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-Trans retinoic acid inhibits Jun N-terminal
          kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol 19:1973-1980, 1999.
12.       Sueoka N, Lee HY, Walsh GL, Hong WK, Kurie JM. Post-Translational mechanisms contribute to the suppression
          of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res 59:3838-
          3844, 1999.
13.       Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters
          KMW, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell
          lung carcinoma. J Clin Oncol 17(8):2309-2315, 1999.
14.       Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L. Loss of Fhit is frequent in stage
          I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59:4798-4803, 1999.
15.       Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, Hong WK, Lotan R. Differential responses of
          normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer
          Res 5(2):431-437, 1999.
16.       Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F,
          Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-
          Soler R, Pisters KM, Putnam JB jR, Richli WR, Savin M, Waugh MK, et al. Adenovirus-mediated p53 gene transfer
          in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):7630771, 1999.
17.       Nemunaitis J, Swisher SG, Timmons T, Connors D, Mach M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL,
          Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R,
          Pisters KM, Putnam JB, Richli WR, Walsh GL, et al. Adenovirus-mediated p53 gene transfer in sequence with
          cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 18(3):609-622, 2000.
18.       Sueoka N, Lee H-Y, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-like
          growth factor binding protein-6 inhibits the growth of human bronchial epithelial cells and increases in abundance
          with all-trans retinoic acid treatment. Am J Respir Cell Mol Biol, 23(3):297-303, 2000.
19.       Sueoka N, Lee H-Y, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. Insulin-like
          growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene,
          19(38):4432-6, 2000.
20.       Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu
          D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous
          metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6(8):2973-2979, 2000.
21.       Liu B, Lee H-Y, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct functional interactions between
          IGFBP-3 and RXR-  regulate transcriptional signaling and apoptosis. J Biol Chem 275(43):33607-33613, 2000.
22.      Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR, Cobb MH, Mangelsdorf DJ,
          Kurie JM. Stress pathhway activation induces phosphorylation of retinoid X receptor. J Biol Chem, 275(41):32193-
          32199, 2000.



    PHS 398/2590 (Rev. 05/01)                                     Page _______                   Biographical Sketch Format Page   
                               Principal Investigator/Program Director (Last, first, middle):   Kurie, Jonathan M.
C. Research Support

Ongoing Research Support
Sidney Kimmel Foundation                                    Kurie (PI)            06/01/99 – 07/30/02
Ras-Dependent Pathways as Mediators of Retinoid-Induced Lung Cancer Chemoprevention.
The major goal of this project is to understand the role of ras-independent pathways in the growth inhibitory effects of
retinoids in the bronchial epithelium.
Role: PI

S/P 5P50 CA70907 (PP-4)
Lung Cancer SPORE Grant, Project 4                          Kurie (PI)            09/01/99 – 03/31/04
NIH/NCI
Retinoid Prevention of Lung Cancer in Former Smokers.
The major goal of this project is to investigate the lung cancer chemopreventive effects of 9-cis retinoic acid vs 13-ris
retinoic acid plus -tocopherol in former smokers.
Role: PI

5-U01-CA84306-01                                           Kurie (PI)              09/25/99 – 09/24/04
NIH/NCI
Creation and Characterization of Mouse Models of Human Lung Cancer.
The major goal of this project is to create and characterize k-ras transgenic mice. My role is to evaluate the efficacy of
retinoids and other agents in lung cancer chemoprevention in this model.
Role: PI

1 R01 CA80686-01A1                                           Kurie (PI)            06/01/00 – 05/31/05
NIH
Retinoid Signaling in New Lung Cancer Prevention Models.
The major goal of this project is to investigate the role of MKK4 and MKP1 in retained resistance in non-small cell lung
cancer cells.
Role: PI

DAMD17-01-1-0689                                            Hong (PI)               03/15/01-03/1506
United States Department of the Army
Biology, Education, Screening, Chemoprevention and Treatment (BESCT) Lung Cancer Program.
Novel strategies for lung cancer chemoprevention. The major goal of this special program, which has been funded
through a bill already signed by President Clinton, is to reduce the impact of lung cancer by: 1) establishing a nationwide
network of hospitals to evaluate patients with a wide range of lung cancers, and use this data to create a new prognostic
model; 2) creating high-impact educational materials to reduce smoking rates in teenagers and young adults; 3)
investigating the use of low-dose helical CT scanning to detect early-stage lung cancers: 4) investigating the use of
chemopreventive regimens in patients with lung premalignancy; and 5) analyzing 30 prognostic biomarkers to determine
effective treatment strategies and use innovative combinations of chemotherapy, radiation, biological agents and viral-
based therapies to treat all stages of lung cancer.
Role: Co-Investigator

R01 CA77203-1                                                         Kurie (PI)                      07/01/01 – 06/30/06
NIH
S/C 3P50 CA70907
IGFBPG: A Target in Lung Cancer Prevention.
Role: PI

Completed Research Support
R29 CA67353-4                                              Kurie (PI)               04/01/95-03/31/01
NIH
Retinoid Signaling in Human Bronchial Epithelial Cells.
To study the expression and function of retinoid receptors (RAR nd RXR gene families) in normal, premalignant, and
malignant HBE cell lines and in biopsies of benign, dysplastic, and malignant bronchial tissue from patients.
To examine retinoid-induced changes in the growth, viability, and squamous differentiation of normal, premalignant, and
malignant HBE cell lines.To investigate the role of specific receptors in mediating retinoid actions in HBE cell lines.
Role: PI

   PHS 398/2590 (Rev. 05/01)                                               Page _______                        Biographical Sketch Format Page   
                           Principal Investigator/Program Director (Last, first, middle): Kurie, Jonathan M.
 U19 CA68437-05                                                  Hong (PI)                       09/25/01-07/31/01
NIH/NCI
Lung Cancer Chemoprevention Research Program: Project 1 Chemoprevention Trial in Former Smokers.
The major goal of this project is to develop effective chemoprevention approaches to reduce lung cancer incidence,
especially in former smokers at high risk.
Role: Co-Investigator




   PHS 398/2590 (Rev. 05/01)                               Page _______                  Biographical Sketch Format Page   

				
DOCUMENT INFO
Shared By:
Categories:
Tags: stages, lung, cancer
Stats:
views:48
posted:3/17/2009
language:English
pages:4